By diminishing the risk of heart failure in diabetic patients and lowering the incidence of major cardiovascular events in those with both diabetes and heart failure, SGLT2 inhibitors ultimately decrease unnecessary hospitalizations and enhance the overall quality of life for these individuals. Here, SLC5A2 is linked to diabetes mellitus.